BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34814007)

  • 1. Regulation of 11β-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients.
    Morgan SA; Berryman DE; List EO; Lavery GG; Stewart PM; Kopchick JJ
    Growth Horm IGF Res; 2022 Feb; 62():101440. PubMed ID: 34814007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
    Stewart PM; Toogood AA; Tomlinson JW
    Horm Res; 2001; 56 Suppl 1():1-6. PubMed ID: 11786677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone (GH) or insulin-like growth factor (IGF)-I represses 11beta-hydroxysteroid dehydrogenase type 1 (HSD1) mRNA expression in 3T3-L1 cells and its activity in their homogenates.
    Morita J; Hakuno F; Hizuka N; Takahashi S; Takano K
    Endocr J; 2009; 56(4):561-70. PubMed ID: 19352050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of regulation of 11beta-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism.
    Sigurjonsdottir HA; Andrew R; Stimson RH; Johannsson G; Walker BR
    Eur J Endocrinol; 2009 Sep; 161(3):375-80. PubMed ID: 19549748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone (GH) substitution in GH-deficient patients inhibits 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue.
    Paulsen SK; Pedersen SB; Jørgensen JO; Fisker S; Christiansen JS; Flyvbjerg A; Richelsen B
    J Clin Endocrinol Metab; 2006 Mar; 91(3):1093-8. PubMed ID: 16368752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11β-HSD1 contributes to age-related metabolic decline in male mice.
    Morgan SA; Gathercole LL; Hassan-Smith ZK; Tomlinson J; Stewart PM; Lavery GG
    J Endocrinol; 2022 Dec; 255(3):117-129. PubMed ID: 36205523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
    Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
    Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of repression of 11β-hydroxysteroid dehydrogenase type 1 by growth hormone in 3T3-L1 adipocytes.
    Muraoka T; Hizuka N; Fukuda I; Ishikawa Y; Ichihara A
    Endocr J; 2014; 61(7):675-82. PubMed ID: 24759003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle.
    Morgan SA; Sherlock M; Gathercole LL; Lavery GG; Lenaghan C; Bujalska IJ; Laber D; Yu A; Convey G; Mayers R; Hegyi K; Sethi JK; Stewart PM; Smith DM; Tomlinson JW
    Diabetes; 2009 Nov; 58(11):2506-15. PubMed ID: 19675138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M
    Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome.
    Loerz C; Maser E
    J Steroid Biochem Mol Biol; 2017 Nov; 174():65-71. PubMed ID: 28765040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
    Masuzaki H; Flier JS
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1.
    Lavery GG; Zielinska AE; Gathercole LL; Hughes B; Semjonous N; Guest P; Saqib K; Sherlock M; Reynolds G; Morgan SA; Tomlinson JW; Walker EA; Rabbitt EH; Stewart PM
    Endocrinology; 2012 Jul; 153(7):3236-48. PubMed ID: 22555437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement.
    Swords FM; Carroll PV; Kisalu J; Wood PJ; Taylor NF; Monson JP
    Clin Endocrinol (Oxf); 2003 Nov; 59(5):613-20. PubMed ID: 14616886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 11β-Hydroxysteroid dehydrogenase type 1 shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adipose tissue.
    Wang Y; Yan C; Liu L; Wang W; Du H; Fan W; Lutfy K; Jiang M; Friedman TC; Liu Y
    Am J Physiol Endocrinol Metab; 2015 Jan; 308(1):E84-95. PubMed ID: 25389364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
    Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
    Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice.
    Liu Y; Nakagawa Y; Wang Y; Sakurai R; Tripathi PV; Lutfy K; Friedman TC
    Diabetes; 2005 Jan; 54(1):32-40. PubMed ID: 15616008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
    Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
    J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.